K27M midline gliomas display malignant progression by imaging and histology
Standard
K27M midline gliomas display malignant progression by imaging and histology. / Vettermann, Franziska J; Neumann, Julia E; Suchorska, Bogdana; Bartenstein, Peter; Giese, Armin; Dorostkar, Mario M; Albert, Nathalie L; Schüller, Ulrich.
in: NEUROPATH APPL NEURO, Jahrgang 43, Nr. 5, 08.2017, S. 458-462.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › Andere (Vorworte u.ä.) › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - K27M midline gliomas display malignant progression by imaging and histology
AU - Vettermann, Franziska J
AU - Neumann, Julia E
AU - Suchorska, Bogdana
AU - Bartenstein, Peter
AU - Giese, Armin
AU - Dorostkar, Mario M
AU - Albert, Nathalie L
AU - Schüller, Ulrich
N1 - Letter
PY - 2017/8
Y1 - 2017/8
N2 - K27M midline gliomas are diffuse gliomas that usually occur in children and young adults and arise in midline structures of the brain, the brain stem and the spinal cord. They are defined by point mutations within the chromatin modifiers H3 and are usually associated with a bad clinical outcome [1,2,3]. As such, they are represented as a new separate entity in the new version of the WHO classification for tumors of the central nervous system. Interestingly, these tumors display a huge histological variability [4] and diagnoses currently range from low grade astrocytoma (WHO-grade II) to glioblastoma (WHO-grade IV). This article is protected by copyright. All rights reserved.
AB - K27M midline gliomas are diffuse gliomas that usually occur in children and young adults and arise in midline structures of the brain, the brain stem and the spinal cord. They are defined by point mutations within the chromatin modifiers H3 and are usually associated with a bad clinical outcome [1,2,3]. As such, they are represented as a new separate entity in the new version of the WHO classification for tumors of the central nervous system. Interestingly, these tumors display a huge histological variability [4] and diagnoses currently range from low grade astrocytoma (WHO-grade II) to glioblastoma (WHO-grade IV). This article is protected by copyright. All rights reserved.
U2 - 10.1111/nan.12371
DO - 10.1111/nan.12371
M3 - Other (editorial matter etc.)
C2 - 27997032
VL - 43
SP - 458
EP - 462
JO - NEUROPATH APPL NEURO
JF - NEUROPATH APPL NEURO
SN - 0305-1846
IS - 5
ER -